Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt No Debt
ISR's Cash-to-Debt is ranked higher than
94% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.62 vs. ISR: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
ISR' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.05  Med: N/A Max: No Debt
Current: No Debt
Equity-to-Asset 0.88
ISR's Equity-to-Asset is ranked higher than
97% of the 184 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.58 vs. ISR: 0.88 )
Ranked among companies with meaningful Equity-to-Asset only.
ISR' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.18  Med: 0.84 Max: 0.92
Current: 0.88
-1.18
0.92
Piotroski F-Score: 3
Altman Z-Score: 3.95
Beneish M-Score: -2.27
WACC vs ROIC
11.49%
-73.69%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -126.29
ISR's Operating Margin % is ranked lower than
88% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.86 vs. ISR: -126.29 )
Ranked among companies with meaningful Operating Margin % only.
ISR' s Operating Margin % Range Over the Past 10 Years
Min: -169.05  Med: -100.34 Max: -56.56
Current: -126.29
-169.05
-56.56
Net Margin % -121.77
ISR's Net Margin % is ranked lower than
84% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.79 vs. ISR: -121.77 )
Ranked among companies with meaningful Net Margin % only.
ISR' s Net Margin % Range Over the Past 10 Years
Min: -167.39  Med: -92.01 Max: -54.25
Current: -121.77
-167.39
-54.25
ROE % -36.83
ISR's ROE % is ranked lower than
77% of the 182 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.30 vs. ISR: -36.83 )
Ranked among companies with meaningful ROE % only.
ISR' s ROE % Range Over the Past 10 Years
Min: -75.03  Med: -46.81 Max: -16.5
Current: -36.83
-75.03
-16.5
ROA % -32.89
ISR's ROA % is ranked lower than
80% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.23 vs. ISR: -32.89 )
Ranked among companies with meaningful ROA % only.
ISR' s ROA % Range Over the Past 10 Years
Min: -60.54  Med: -40 Max: -14.86
Current: -32.89
-60.54
-14.86
ROC (Joel Greenblatt) % -92.18
ISR's ROC (Joel Greenblatt) % is ranked lower than
77% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.88 vs. ISR: -92.18 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ISR' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -365.49  Med: -87.14 Max: -33.47
Current: -92.18
-365.49
-33.47
3-Year Revenue Growth Rate -12.80
ISR's 3-Year Revenue Growth Rate is ranked lower than
82% of the 148 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.10 vs. ISR: -12.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ISR' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -100 Max: 12.7
Current: -12.8
0
12.7
3-Year EBITDA Growth Rate -5.40
ISR's 3-Year EBITDA Growth Rate is ranked lower than
74% of the 126 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.80 vs. ISR: -5.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ISR' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -26.4 Max: 401.3
Current: -5.4
0
401.3
3-Year EPS without NRI Growth Rate -6.50
ISR's 3-Year EPS without NRI Growth Rate is ranked lower than
68% of the 122 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.10 vs. ISR: -6.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ISR' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -32 Max: 278
Current: -6.5
0
278
GuruFocus has detected 3 Warning Signs with IsoRay Inc $ISR.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ISR's 30-Y Financials

Financials (Next Earnings Date: 2017-09-13 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

ISR Guru Trades in Q2 2016

Jeff Auxier 14,218 sh (unchged)
» More
Q3 2016

ISR Guru Trades in Q3 2016

Jeff Auxier 14,218 sh (unchged)
» More
Q4 2016

ISR Guru Trades in Q4 2016

Jeff Auxier 14,218 sh (unchged)
» More
Q1 2017

ISR Guru Trades in Q1 2017

Jeff Auxier 14,218 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ISR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 339112    SIC: 3841
Compare:NAS:BLFS, AMEX:INFU, NAS:VLRX, AMEX:RVP, NAS:EKSO, NAS:CASM, AMEX:DXR, OTCPK:LDSYF, NAS:PDEX, NAS:BMRA, NAS:ATEC, AMEX:MLSS, NAS:LENS, OTCBB:NEPH, OTCPK:ERGVF, OTCPK:REPR, OTCPK:IGAP, NAS:AKER, OTCPK:STXS, OTCPK:UEEC » details
Traded in other countries:AAJ.Germany,
Headquarter Location:USA
IsoRay Inc offers solutions for the treatment and diagnosis of disease using medical isotopes. The Company treats prostate cancer, brain, liver, breast cancer, colorectal cancer, gynecological cancer, lung cancer, ocular melanoma and pancreatic cancer.

IsoRay Inc was organized under Minnesota law in 1983. The Company develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. In 2003, the Company obtained clearance from the FDA for treatment for all solid tumor applications using Cesium-131. Such applications include prostate cancer; ocular melanoma; head, neck and lung tumors; breast cancer; liver cancer; brain cancer; colorectal cancer; gynecological cancer; esophageal cancer; and pancreatic cancer. The brachytherapy seed form of Cesium-131 may be used in surface, interstitial and intracavity applications for tumors with known radio sensitivity. In March 2011, the Company received clearance to commercially deliver Proxcelan Cesium-131 brachytherapy seeds that are preloaded into bioabsorbable braided strands into Europe. Its products include Proxcelan Cesium-131, GliaSite RTS is the only FDA cleared balloon catheter device used in the treatment of brain cancer. The GliaSite RTS and the Company's brachytherapy products used in non-prostate applications typically compete with external beam radiation therapy (EBRT), which can be provided as conventional or intensity modulated radiation therapy, or as stereotactic radiosurgery, a technique that delivers high doses of radiation to a target in a much lower number of sessions than other forms of EBRT. The Company's present and future activities in the development, manufacture and sale of cancer therapy products are subject to extensive laws, regulations, regulatory approvals and guidelines.

Ratios

vs
industry
vs
history
PB Ratio 2.56
ISR's PB Ratio is ranked higher than
64% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.56 vs. ISR: 2.56 )
Ranked among companies with meaningful PB Ratio only.
ISR' s PB Ratio Range Over the Past 10 Years
Min: 0.31  Med: 3.42 Max: 23.68
Current: 2.56
0.31
23.68
PS Ratio 6.95
ISR's PS Ratio is ranked lower than
79% of the 180 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.01 vs. ISR: 6.95 )
Ranked among companies with meaningful PS Ratio only.
ISR' s PS Ratio Range Over the Past 10 Years
Min: 0.57  Med: 5.76 Max: 31.18
Current: 6.95
0.57
31.18
Current Ratio 10.46
ISR's Current Ratio is ranked higher than
98% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.54 vs. ISR: 10.46 )
Ranked among companies with meaningful Current Ratio only.
ISR' s Current Ratio Range Over the Past 10 Years
Min: 0.82  Med: 7.12 Max: 24.59
Current: 10.46
0.82
24.59
Quick Ratio 10.18
ISR's Quick Ratio is ranked higher than
98% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.67 vs. ISR: 10.18 )
Ranked among companies with meaningful Quick Ratio only.
ISR' s Quick Ratio Range Over the Past 10 Years
Min: 0.68  Med: 6.67 Max: 24.21
Current: 10.18
0.68
24.21
Days Inventory 32.29
ISR's Days Inventory is ranked higher than
92% of the 175 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 124.79 vs. ISR: 32.29 )
Ranked among companies with meaningful Days Inventory only.
ISR' s Days Inventory Range Over the Past 10 Years
Min: 29.03  Med: 39.96 Max: 64.02
Current: 32.29
29.03
64.02
Days Sales Outstanding 69.10
ISR's Days Sales Outstanding is ranked higher than
71% of the 153 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.76 vs. ISR: 69.10 )
Ranked among companies with meaningful Days Sales Outstanding only.
ISR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 46.3  Med: 62.07 Max: 83.11
Current: 69.1
46.3
83.11

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -16.70
ISR's 3-Year Average Share Buyback Ratio is ranked lower than
80% of the 120 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -3.20 vs. ISR: -16.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ISR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -110.2  Med: -14.65 Max: 0
Current: -16.7
-110.2
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 9.50
ISR's Price-to-Net-Cash is ranked higher than
83% of the 48 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.17 vs. ISR: 9.50 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ISR' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1  Med: 8.22 Max: 157.5
Current: 9.5
1
157.5
Price-to-Net-Current-Asset-Value 3.00
ISR's Price-to-Net-Current-Asset-Value is ranked higher than
87% of the 109 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.18 vs. ISR: 3.00 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ISR' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.71  Med: 5.69 Max: 175
Current: 3
0.71
175
Price-to-Tangible-Book 2.56
ISR's Price-to-Tangible-Book is ranked higher than
73% of the 154 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.77 vs. ISR: 2.56 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ISR' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.35  Med: 3.63 Max: 71.78
Current: 2.56
0.35
71.78
Price-to-Median-PS-Value 1.22
ISR's Price-to-Median-PS-Value is ranked lower than
56% of the 148 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.14 vs. ISR: 1.22 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ISR' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.11  Med: 1.07 Max: 34.29
Current: 1.22
0.11
34.29
Earnings Yield (Greenblatt) % -20.28
ISR's Earnings Yield (Greenblatt) % is ranked lower than
93% of the 267 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.18 vs. ISR: -20.28 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ISR' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 360.2  Med: 1093.65 Max: 16057.5
Current: -20.28
360.2
16057.5

More Statistics

Revenue (TTM) (Mil) $4.51
EPS (TTM) $ -0.11
Beta1.54
Short Percentage of Float3.86%
52-Week Range $0.48 - 1.06
Shares Outstanding (Mil)55.02

Analyst Estimate

Jun17 Jun19 Jun20
Revenue (Mil $) 5 15 18
EPS ($) -0.09 0.08 0.09
EPS without NRI ($) -0.09 0.08 0.09
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ISR

Headlines

Articles On GuruFocus.com
IsoRay Announces Third Quarter Fiscal 2017 Financial Results May 10 2017 
IsoRay Announces Study Accepted for Publication in The International Journal of Radiation Oncology, May 03 2017 
Isoray, Inc. Announces Appointment of PCG Advisory Group as Investor, Public and Digital Communicati Aug 10 2015 
IsoRay's Cesium-131 Cancer Fighting Portfolio was on Display at the American Association of Physicis Jul 16 2015 
IsoRay's Cesium-131 Selected by Chicago Prostate Cancer Center for Use in the Launch of a Study of t Jun 29 2015 
IsoRay's Cancer Fighting Isotope Cesium-131 Will Be Featured in Four Oral Presentations at the Ameri Apr 08 2015 
UPMC Study Reports IsoRay's Cesium-131 Prostate Treatment Provides Strong Cancer Control With Lower Jan 20 2015 
IsoRay's Cesium-131 Therapy Takes Center Stage at Russia's Neftyanik Hospital a Center of Excellence Jan 13 2015 
IsoRay Ranked 5th Highest Share Price Percentage Gainer (192%) in 2014 Among 2417 Companies Listed o Jan 12 2015 
IsoRay's Cesium-131 Used in World's First Veterinary Implant in a Horse With Cancer Dec 08 2014 

More From Other Websites
IsoRay, Inc. :ISR-US: Earnings Analysis: Q3, 2017 By the Numbers : May 26, 2017 May 26 2017
IsoRay reports 3Q loss May 10 2017
IsoRay Announces Third Quarter Fiscal 2017 Financial Results May 10 2017
IsoRay Announces Study Accepted for Publication in The International Journal of Radiation Oncology,... May 03 2017
ETFs with exposure to IsoRay, Inc. : April 27, 2017 Apr 27 2017
IsoRay, Inc. to Present at the Planet MicroCap Showcase 2017 Apr 18 2017
IsoRay, Inc. :ISR-US: Earnings Analysis: Q2, 2017 By the Numbers : March 21, 2017 Mar 21 2017
IsoRay Announces Final Court Approval of Class Action Settlement Mar 09 2017
IsoRay Announces Second Quarter Fiscal 2017 Financial Results Feb 08 2017
MicroCap Review Magazine Winter/Spring 2017 Issue Now Available Feb 07 2017
IsoRay, Inc. to Present at the 2nd Annual Disruptive Growth & Healthcare Conference Feb 02 2017
ETFs with exposure to IsoRay, Inc. : January 19, 2017 Jan 19 2017
Purcell Julie & Lefkowitz LLP Is Investigating IsoRay, Inc. for Potential Breaches Of Fiduciary Duty... Jan 11 2017
IsoRay Medical, Inc. Discusses Cesium-131 and its Applications in New SNNLive Video Interview on... Dec 22 2016
IsoRay, Inc. Announces the Launch of a Pilot Study Using Intraoperative Placement of Cesium-131... Dec 21 2016
ETFs with exposure to IsoRay, Inc. : December 7, 2016 Dec 07 2016
IsoRay to Present at 9th Annual LD Micro Investor Conference Nov 30 2016
IsoRay Announces "Cesium-131 Brachytherapy for Salvage of Recurrent High Grade Glioma" Poster... Nov 29 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)